Monod Bio, a Seattle-based AI-enabled protein design company, and SignalChem Biotech Inc., a wholly-owned subsidiary of Sino Biological, Inc. (SZSE: 301047), have announced a non-exclusive licensing agreement covering Monod Bio’s proprietary LuxSit de novo luciferase technology and NovoBodies. This partnership allows SignalChem Biotech to incorporate these AI-designed protein technologies into custom luminescent assay development and protein-fusion services for third-party customers, marking a significant step in the integration of AI-enabled life science tools into commercial services.
The agreement expands SignalChem’s specialized contract research organization (CRO) capabilities and aligns with Sino Biological’s broader strategy of incorporating AI-enabled technologies across its global life science tools and services portfolio. By leveraging Monod Bio’s innovative protein designs, researchers can potentially obtain high-quality discovery candidates more rapidly, addressing complex biological questions and advancing research programs more efficiently.
Monod Bio’s LuxSit is an AI-designed luciferase engineered for use in robust luminescent biosensors, while its NovoBodies are compact, highly stable binding proteins designed for high-performance recognition of various targets. Together, these technologies provide versatile tools for developing customized assays and discovery workflows, offering researchers new options for sensitive and specific detection.
Dr. Rob Burgess, Chief Business Officer of Sino Biological, highlighted the importance of the collaboration: “By incorporating Monod Bio’s AI-designed protein technologies into SignalChem’s custom assay platform, we can help researchers obtain high quality discovery candidates more rapidly. This agreement and the corresponding licensed technology strengthen our ability to help customers address complex biological questions and advance their research programs more efficiently.”
Daniel Silva Manzano, PhD, Chief Executive Officer of Monod Bio, expressed enthusiasm about the partnership: “SignalChem Biotech and Sino Biological have the scientific expertise, customer reach and service infrastructure to bring these technologies to a broad customer base. This partnership expands the reach of our platform and reinforces the value of our Monod Inside model for integrating AI-designed proteins into commercial products and services.”
SignalChem Biotech, a wholly owned subsidiary of Sino Biological, provides specialized reagents and CRO services supporting drug discovery and life science research. Sino Biological is an international life science tools provider with facilities across Asia, North America and Europe. For more information, visit www.sinobiological.com.
Monod Bio uses AI-powered de novo protein design to create novel binders, biosensors, and other functional proteins for research and diagnostic applications. Through its Monod Inside model, Monod Bio partners with life science companies to integrate its technologies into next-generation products and services. For more information, visit monod.bio.
The development of the related business may be affected by various factors, including changes in market demand. Given the company’s broad product portfolio, the revenue associated with this business is not expected to have a material impact on the company’s overall financial performance.
